J Groffen
Overview
Explore the profile of J Groffen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
3936
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fei F, Lim M, George A, Kirzner J, Lee D, Seeger R, et al.
Leukemia
. 2014 Aug;
29(4):788-97.
PMID: 25134458
Precursor B-lineage acute lymphoblastic leukemia (pre-B ALL) affects hematopoietic development and therefore is associated with immune deficiencies that can be further exacerbated by chemotherapy. It is unclear if and when...
2.
Fei F, Abdel-Azim H, Lim M, Arutyunyan A, von Itzstein M, Groffen J, et al.
Leukemia
. 2013 Jun;
27(12):2385-8.
PMID: 23760399
No abstract available.
3.
Yu M, Gang E, Parameswaran R, Stoddart S, Fei F, Schmidhuber S, et al.
Blood Cancer J
. 2012 Jul;
1(4):e14.
PMID: 22829135
No abstract available.
4.
Parameswaran R, Yu M, Lyu M, Lim M, Rosenblum M, Groffen J, et al.
Leukemia
. 2012 Mar;
26(8):1786-96.
PMID: 22373785
Acute lymphoblastic leukemia (ALL) is the most common malignancy affecting children and a major cause of mortality from hematopoietic malignancies in adults. A substantial number of patients become drug resistant...
5.
Haataja L, Fioretos T, Voncken J, Groffen J, Heisterkamp N
Int J Oncol
. 2011 May;
5(1):47-9.
PMID: 21559556
Interferon-alfa (IFN-alpha) is one of the most effective drugs in the treatment of chronic myeloid leukemia (CML). Recently, IFN-alpha has also been tried in the treatment of Ph-positive acute lymphoid...
6.
Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N
Leukemia
. 2011 Apr;
25(8):1314-23.
PMID: 21483439
The bone marrow (BM) stromal niche can protect acute lymphoblastic leukemia (ALL) cells against the cytotoxicity of chemotherapeutic agents and is a possible source of relapse. The stromal-derived factor-1 (SDF-1)/CXCR4...
7.
Fei F, Stoddart S, Muschen M, Kim Y, Groffen J, Heisterkamp N
Leukemia
. 2010 Jan;
24(4):813-20.
PMID: 20111071
Dasatinib is a potent dual Abl/Src inhibitor approved for treatment of Philadelphia chromosome-positive (Ph-positive) leukemias. At a once-daily dose and a relatively short half-life of 3-5 h, tyrosine kinase inhibition...
8.
Zhang B, Groffen J, Heisterkamp N
Leukemia
. 2007 Mar;
21(6):1189-97.
PMID: 17392819
In leukemia patients, resistance to drug treatment develops while the malignant cells can interact with and derive support from their microenvironment, such as bone marrow stroma. To model this process,...
9.
Mishra S, Pertz V, Zhang B, Kaur P, Shimada H, Groffen J, et al.
Leukemia
. 2006 Nov;
21(1):178-80.
PMID: 17082777
No abstract available.
10.
Mishra S, Zhang B, Groffen J, Heisterkamp N
Leukemia
. 2003 Nov;
18(1):23-8.
PMID: 14603339
Treatment of chronic myelogenous leukemia with a specific inhibitor of the Bcr/Abl tyrosine kinase, imatinib, has shown great promise. However, acute lymphoblastic leukemias that express Bcr/Abl only transiently respond to...